心臟類澱粉沉積症市場規模、佔有率和成長分析：按診斷、疾病類型、治療方法、給藥途徑、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球心臟類澱粉沉積症市場價值為 28.5 億美元，預計到 2025 年將成長至 31 億美元，到 2033 年將成長至 61.4 億美元，在預測期（2026-2033 年）內複合年成長率為 8.9%。

心臟類澱粉沉積症樣變性市場深受保險報銷機制的影響，有利的健保覆蓋範圍能夠改善患者的就醫途徑，並推動收入成長。各地區正在湧現創新性的協議，旨在拓展治療選擇，同時兼顧預算限制。這種動態環境促使生物技術公司探索先進療法，例如基於RNA的沉默劑，以降低轉甲狀腺素蛋白生成為研究的實例。因此，不斷擴充的治療方案不僅為無法耐受現有藥物的患者提供了新的選擇，也刺激了對影像學和生物標記服務的需求。這一趨勢正在市場內形成良性循環的成長和創新，預示著心臟類澱粉沉積症樣變性治療的管理和可及性前景光明。

全球心臟類澱粉沉積症市場的成長要素

全球心臟類澱粉沉積症變性市場正受到醫療專業人員教育程度提升和篩檢範圍擴大的顯著推動，這些因素提高了人們對該疾病相關症狀的認知。隨著醫療專業人員在鑑別心臟類澱粉沉積症樣變性與其他類型心肌病方面不斷加深專業知識，轉診至專科治療中心的機制也日益完善。這種認知的提高推動了對診斷工具和治療方案的需求，進而吸引了製藥業的投資，加速了市場成長。因此，越來越多的患者得到診斷和治療，從而創造了持續的收入，並促進了對創新療法的進一步研究。此外，這些發展也促進了合作網路的建立，從而改善了臨床試驗參與者的招募流程，加速了新療法的上市。

全球心臟類澱粉沉積症市場的限制因素

由於複雜的生產過程和有限的市場競爭導致新療法高成本，全球心臟類澱粉沉積症治療市場面臨許多挑戰。高昂的價格給保險公司帶來壓力，並可能導致患者自付費用增加。因此，許多患者可能會延遲開始治療，甚至完全停止處方治療。此外，醫療保健系統通常優先考慮成本效益，導致醫保覆蓋藥物種類有限，且預先核准要求更加嚴格，這使得一些合格的患者無法獲得所需的治療。這種經濟負擔也導致一些醫療專業人員在開立最新療法時猶豫不決，進一步阻礙了市場成長。

全球心臟類澱粉沉積症樣變性市場趨勢

受精準診斷技術進步的推動，全球心臟類澱粉沉積症市場呈現顯著上升趨勢。分子影像和生物標記分析的創新進展使得早期、準確地識別各種心臟類澱粉沉積症樣變性亞型成為可能，從而促進個人化治療策略的發展。人工智慧（AI）與影像資料的融合進一步提高了診斷準確性，降低了不確定性，並實現了及時介入。因此，醫療專業人員對可靠的診斷解決方案的需求日益成長，而製造商則專注於投資策略合作並獲得監管部門的批准。這項發展不僅改善了患者的治療效果，也為科技公司開闢了新的商機，並擴大了其在各種醫療環境中的市場滲透率。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系圖譜
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球心臟類澱粉沉積症市場規模：依診斷分類

• 診斷影像
• 生物標記檢測
• 切片檢查和組織病理學
• 基因檢測
• 其他

全球心臟類澱粉沉積症市場規模：依疾病類型分類

• 轉甲狀腺素類澱粉沉積症（ATTR）
• 輕鏈類澱粉沉積症（AL）

全球心臟類澱粉沉積症市場規模：依治療方法分類

• 轉甲狀腺素穩定劑
• 基因靜默療法
• 化療
• 單株抗體
• 支持性護理
• 其他

全球心臟類澱粉沉積症市場規模：依給藥途徑分類

• 口服
• 靜脈
• 皮下

全球心臟類澱粉沉積症市場規模：依最終用戶分類

• 醫院
• 循環系統專科診所
• 門診手術中心
• 診斷中心

全球心臟類澱粉沉積症市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球心臟類澱粉沉積症市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc
• Alnylam Pharmaceuticals Inc
• Ionnis Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc
• BridgeBio Pharma Inc
• Eidos Therapeutics Inc
• Intellia Therapeutics Inc
• Prothena Corporation plc
• Alexion Pharmaceuticals Inc
• AstraZeneca plc
• GlaxoSmithKline plc
• Sanofi SA
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson Services Inc
• Merck & Co Inc
• Bristol Myers Squibb Company
• Amgen Inc
• Neurimmune AG
• AC Immune SA

結論與建議

Global Cardiac Amyloidosis Market size was valued at USD 2.85 Billion in 2024 and is poised to grow from USD 3.1 Billion in 2025 to USD 6.14 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026-2033).

The cardiac amyloidosis market is significantly influenced by reimbursement frameworks, as favorable insurance coverage enhances patient access and drives revenue growth. In various regions, innovative agreements among insurance providers have emerged, focusing on balancing budgetary constraints while increasing treatment options. This dynamic landscape propels biotech companies to explore advanced therapies, such as RNA-based silencers, exemplified by studies targeting the reduction of transthyretin production. Consequently, the expanding therapeutic pipeline not only offers alternatives for patients who cannot tolerate existing medications but also stimulates demand for diagnostic imaging and biomarker services. This development fosters a continuous cycle of growth and innovation within the market, signifying a promising future for cardiac amyloidosis management and treatment accessibility.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiac Amyloidosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiac Amyloidosis Market Segments Analysis

Global cardiac amyloidosis market is segmented by diagnosis, disease type, treatment, route of administration, end user, distribution channel and region. Based on diagnosis, the market is segmented into Imaging, Biomarker Testing, Biopsy & Histopathology, Genetic Testing and Others. Based on disease type, the market is segmented into Transthyretin Amyloidosis (ATTR) and Light Chain Amyloidosis (AL). Based on treatment, the market is segmented into Transthyretin Stabilizers, Gene Silencing Therapies, Chemotherapy, Monoclonal Antibodies, Supportive Care and Others. Based on route of administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on end user, the market is segmented into Hospitals, Specialty Cardiology Clinics, Ambulatory Surgical Centers and Diagnostic Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiac Amyloidosis Market

The global market for cardiac amyloidosis is being significantly driven by enhanced education for healthcare professionals and widespread screening initiatives that improve the recognition of symptoms associated with the condition. As healthcare providers gain expertise in differentiating cardiac amyloidosis from other forms of cardiomyopathy, referral systems to specialized treatment centers are becoming more effective. This increased awareness has amplified the demand for diagnostic tools and therapeutic solutions, which in turn attracts pharmaceutical investment and promotes market growth. As a result, more patients are being diagnosed and managed, generating ongoing revenue and encouraging further research into innovative treatments. Additionally, these advancements facilitate collaborative networks that improve the enrollment process for clinical trials, thereby expediting the introduction of new therapies.

Restraints in the Global Cardiac Amyloidosis Market

The global market for cardiac amyloidosis therapies faces significant obstacles due to the high costs associated with new treatments, which arise from intricate manufacturing processes and limited market competition. These premium prices can create challenges for insurance providers and result in increased out-of-pocket expenses for patients. Consequently, many individuals may experience delays in starting treatment or may even stop their prescribed therapies altogether. Additionally, healthcare systems often focus on cost-effectiveness, leading to restrictive formularies and stringent prior authorization requirements that leave a portion of the eligible patient population without access to needed therapies. This financial strain also dissuades some healthcare professionals from prescribing the latest treatment options, further hindering market growth.

Market Trends of the Global Cardiac Amyloidosis Market

The Global Cardiac Amyloidosis market is experiencing a significant upward trend fueled by advancements in precision diagnostics. Innovative developments in molecular imaging and biomarker profiling are facilitating earlier and more precise identification of various cardiac amyloidosis subtypes, encouraging tailored treatment strategies. The incorporation of artificial intelligence in imaging data further enhances diagnostic accuracy, mitigating uncertainty and fostering timely interventions. Consequently, healthcare providers are increasingly seeking robust diagnostic solutions, spurring manufacturers to invest in strategic collaborations and seek regulatory approvals. This evolution not only leads to improved patient outcomes but also opens new revenue opportunities for technology firms, broadening market penetration across diverse healthcare settings.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cardiac Amyloidosis Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Imaging
• Biomarker Testing
• Biopsy & Histopathology
• Genetic Testing
• Others

Global Cardiac Amyloidosis Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Transthyretin Amyloidosis (ATTR)
• Light Chain Amyloidosis (AL)

Global Cardiac Amyloidosis Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Transthyretin Stabilizers
• Gene Silencing Therapies
• Chemotherapy
• Monoclonal Antibodies
• Supportive Care
• Others

Global Cardiac Amyloidosis Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Cardiac Amyloidosis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Cardiology Clinics
• Ambulatory Surgical Centers
• Diagnostic Centers

Global Cardiac Amyloidosis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cardiac Amyloidosis Market Size & CAGR (2026-2033)

• North America (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Disease Type, Treatment, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionnis Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurimmune AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AC Immune SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations